THE WHAT? An investor group led by EQT has exited its remaining stake in Swiss skincare firm Galderma via a significant share sale.
THE DETAILS EQT AB, the Abu Dhabi Funding Authority (ADIA) and Auba Funding Pte — backed by Singapore’s sovereign wealth fund GIC — offered their remaining shares in Galderma in a 4.89 billion Swiss francs (US$6.3 billion) transaction. The deal marked the ultimate stage of their exit technique, internally known as “Venture Indigo,” and was expanded twice because of sturdy investor demand.
The buyers initially acquired Galderma from Nestlé in 2019 for round 10.2 billion francs, together with debt. Since then, they’ve regularly lowered their holdings via Galderma’s 2024 IPO and subsequent share placements. In whole, the buyers have generated greater than 20 billion francs in proceeds from their funding. Galderma’s shares have risen greater than 180% because the IPO, supported by sturdy monetary efficiency and demand for merchandise similar to Cetaphil and the injectable dermatitis remedy Nemluvio
THE WHY? The exit displays a profitable non-public fairness funding cycle following Galderma’s public itemizing and robust share worth efficiency.
Supply: Bloomberg
